Table 2.
Univariate and multivariate analyses of clinicopathological parameters for the prediction of overall survival in patients with advanced pancreatic cancer (n = 210)
| Parameters | Univariate analyses | Multivariate analyses | ||
|---|---|---|---|---|
| P | HR (95%CI) | P | HR (95%CI) | |
| Age (years): <65 vs ≥65 | .145 | — | — | — |
| Gender: Male vs Female | .766 | — | — | — |
| TNM stage: IV vs III | .001 | 1.626 (1.212‐2.179) | .03 | 1.422 (1.034‐1.957) |
| Chemotherapy: Yes vs No | .018 | 0.632 (0.432‐0.924) | .066 | 0.698 (0.476‐1.025) |
| Tregs: High vs Low (Median：8.66%) | .007 | 1.458 (1.109‐1.912) | .004 | 1.522 (1.143‐2.028) |
| CD3+ CD4+ T cells: High vs Low (Median：38.99%) | .211 | 1.189 (0.906‐1.56) | — | — |
| CD3+ CD8+ T cells: High vs Low (Median：21.06%) | .494 | 0.909 (0.69‐1.196) | — | — |
| Kras G12V | .002 | 1.616 (1.192‐2.183) | .001 | 1.667 (1.217‐2.028) |
| Mutation vs None | ||||
| Kras G12D | .002 | 1.577 (1.188‐2.092) | .044 | 1.353 (1.009‐1.815) |
| Mutation vs None | ||||
| CA19‐9 level (U/mL) | <.001 | 1.822 (1.367‐2.429) | .009 | 1.488 (1.103‐2.008) |
| ≥1000 vs <1000 | ||||
| CA125 level (U/mL) | <.001 | 0.576 (0.434‐0.764) | .055 | 0.747 (0.555‐1.007) |
| <35 vs ≥35 | ||||
Abbreviation: 95%CI, 95% confidence interval; HR: hazard ratio.